How robust is the evidence supporting the effectiveness of exosomes in costmetics? Where do these exosomes come from? And how large is the market for exosome-infused products?
Artificial Intelligence (AI) is revolutionizing industries across the globe, and one of its most impactful applications is in the biomedical field.
Growth factors are critical controllers of cell behaviour. By providing printability and sustained release, PODS are increasing our ability to harness these key molecules in cell culture and cell therapy
Defining a set of secreted proteins that are associated with morbidities and conditions in later life is helping to develop treatments to increase healthspan and lifespan
Protein gradients, especially of cytokines and chemokines, are essential in biology for guiding cell migration, activating immunity, and orchestrating development. Traditional methods often struggle with unstable delivery, burst release, or limited spatial control. Here, we review common approaches and highlight the befits of PODS as a powerful, next-generation tool for engineering reliable protein gradients.
Researchers in Tokyo have leveraged PODS protein crystals to create a gold-harvesting technology that is environmentally friendly and more selective than most synthetic materials.
A new study led by researchers at the University of Glasgow presents compelling evidence of PODS ability to elevate organoid-based therapies to a new level.
Isolating EVs in a form compatible with downstream next-generation sequencing (NGS), particularly for small RNA analysis, can be technically challenging. But using the right kits to process the samples, many different groups have now developed an efficient workflow that is generating valuable EV microRNA data.
We explore the status of CAR T-cell therapy in the treatment of solid tumors, possible causes of failure, potential solutions, and the progress of CAR T-cell therapy for solid tumors and discuss the possible significance of CAR T-cell therapy for cancer treatment in the future.
CAR-T has been revolutionary, but as an autologous therapy, it is slow and costly. Allogeneic CAR-T cells, known as iNKTS, are now in development and may offer a rapid, cheaper (and perhaps more effective) off-the-shelf solution.
